Duloxetine Opioids

DULOXETINE OPIOIDS t serotonin effects, including possible cases of serotonin syndrome, when opioids (oxycodone, pethidine, pentazocine, tramadol) are given Uncertain Look for signs oft serotonin activity, particularly on initiating therapy... 

Receptor interactions preclinical studies have shown that duloxetine is a potent inhibitor of serotonin and norepinephrine reuptake and a less potent inhibitor of dopamine reuptake. Duloxetine has no significant affinity for dopaminergic, adrenergic, cholinergic, histamin-ergic, opioid, glutamate, and GABA receptors. Duloxetine does not inhibit monoamine oxidase (MAO). 

It is mandatory to set up a realistic goal prior to initiating pain management. Duloxetine, as an adjuvant analgesic, may contribute to pain relief gradually but not instantaneously. Previous studies have demonstrated mild to moderate pain relief in patients who responded to duloxetine treatment. The efficacy and timeline with duloxetine were quite different than analgesics such as opioids or NSAIDs that were not FDA approved for DPN and/or fibromyalgia. 

---